Амбулаторные технологии в лечении варикозной болезни нижних конечностей

В.Я. Хрыщанович, Н.А. Роговой, И.П. Климчук, Д.В. Кресс, Г.Э. Кордзахия

Белорусский государственный медицинский университет, г. Минск, Республика Беларусь; 4-я городская клиническая больница им. Н.Е. Савченко, г. Минск, Республика Беларусь

По данным Всемирной организации здравоохранения варикозной болезнью нижних конечностей (ВБ) страдает каждый третий взрослый человек планеты. В Республике Беларусь насчитывается более 2 миллионов человек с варикозным расширением поверхностных вен нижних конечностей, из них около 400 000 – в г. Минске. Трофические нарушения наблюдаются у 2% пациентов от общего количества населения. По данным исследования RELIЕF (Reflux assEssment and quality of life improvement with micronized Flavonoids in chronic venous insufficiency), которое проводилось с марта 1997 г. по декабрь 1998 г. в 23 странах с участием более 10 000 пациентов с хронической венозной недостаточностью (ХВН), 78% обследованных с симптомами ХВН не получали лечения. На сегодняшний день арсенал хирургических методов лечения ВБ отличается большим разнообразием. В настоящее время в развитых странах отмечается тенденция к росту малоинвазивных вмешательств в лечении ВБ, выполняемых амбулаторно. Среди предложе

ключевые слова: варикозная болезнь нижних конечностей, склеротерапия, хроническая венозная недостаточность, эндовенозная лазерная коагуляция

для цитирования: В.Я. Хрыщанович, Н.А. Роговой, И.П. Климчук, Д.В. Кресс, Г.Э. Кордзахия. Амбулаторные технологии в лечении варикозной болезни нижних конечностей. Неотложная кардиология и кардиоваскулярные риски, 2022, Т. 6, № 2, С. 1730–1736.

Outpatient treatment strategies for lower extremity varicose vein disease

V. Khryschanovich, N. Rogovoy, I. Klimchuk, D. Kress, G. Kordzakhia

According to the World Health Organization, every third adult on the planet suffers from varicose vein disease of the lower extremities (VVD). In the Republic of Belarus there are more than 2 million people with VVD of the superficial veins of the lower extremities, of which about 400,000 reside in Minsk. Trophic disorders are observed in 2% of the total population. According to the RELIEF study (Reflux assurance and quality of life improvement with micronized Flavonoids in chronic venous insufficiency (CVI) – a study conducted from March 1997 to December 1998 in 23 countries with more than 10,000 patients suffering from CVI), 78% patients with symptoms of CVI did not receive treatment. Nowadays, surgical treatment methods for the VVD are very diverse. Currently, in developed countries, there is a trend towards an increase in minimally invasive interventions in the treatment of VVD performed on an outpatient basis. Among the proposed types of invasive methods of treatment, endovenous laser ablation, sclerotherapy, endovenous mechanochemical and radiofrequency obliteration are most widely used.

keywords: varicose vein disease of the lower extremities, sclerotherapy, chronic venous insufficiency, endovenous laser ablation

for references: V. Khryschanovich, N. Rogovoy, I. Klimchuk, D. Kress, G. Kordzakhia. Outpatient treatment strategies for lower extremity varicose vein disease. Neotlozhnaya kardiologiya i kardiovaskulyarnye riski [Emergency cardiology and cardiovascular risks], 2022, vol. 6, no. 2, pp. 1730–1736.

1. Chiesa R., Marone E.M., Limoni C., Volonte M., Schaefer E., Petrini O. Demographic factors and their relationship with the presence of CVI signs in Italy: the 24-cities cohort study. Eur J Vasc Endovasc Surg, 2005, vol. 30, no. 6, pp. 674-680. doi: 10.1016/j.ejvs.2005.06.016.
2. Cornwall J.V., Dore C.J., Lewis J.D. Leg ulcers: epidemiology and aetiology. Br J Surg, 1986, vol. 3, no 9, pp. 693-696. doi: 10.1002/bjs.1800730905.
3. Cesarone M.R., Belcaro G., Nicolaides A.N., Geroulakos G., Griffin M., Incandela L. ‘Real’ epidemiology of varicose veins and chronic venous diseases: the San Valentino Vascular Screening Project. Angiology, 2002, vol. 53, no 2, pp. 119-130. doi: 10.1177/000331970205300201.
4. Rabe E., Pannier F. Societal costs of chronic venous disease in CEAP C4, C5, C6 disease. Phlebology, 2010, vol. 25, suppl. 1, pp. 64-67. doi: 10.1258/phleb.2010.010s09.
5. Lal B.K. Venous ulcers of the lower extremity: definition, epidemiology, and economic and social burdens. Semin Vasc Surg, 2015, vol. 28, no. 1, pp. 3-5. doi: 10.1053/j.semvascsurg.2015.05.002.
6. Davies A.H. The seriousness of chronic venous disease: a review of real-world evidence. Adv Ther, 2019, vol. 36, suppl. 1, pp. 5-12. doi: 10.1007/s12325-019-0881-7.
7. Nicolaides A., Kakkos S., Baekgaard N., Comerota A., de Maeseneer M., Eklof B. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol, 2018, vol. 37, pp. 181-254. doi: 10.23736/ S0392-9590.18.03999-8.
8. Nicolaides A., Kakkos S., Eklof B., Perrin M., Nelzen O., Neglen P. Management of chronic venous disorders of the lower limbs – guidelines according to scientific evidence. Int Angiol, 2014, vol. 33, pp. 87-208.
9. Wittens C., Davies A.H., Bækgaard N., Broholm R., Cavezzi A., Chastanet S. Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg, 2015, vol. 49, pp. 678-737. doi: 10.1016/j.ejvs.2015.02.007.
10.Rossijskie klinicheskie rekomendacii po diagnostike i lecheniyu hronicheskih zabolevanij ven [Russian clinical guidelines for the diagnosis and treatment of chronic vein disease]. Flebologiya, 2018, vol. 12, no. 3, pp. 146-240. doi: 10.17116/ flebo20187031146. (in Russian).
11. Martinez M.J., Bonfill X., Moreno R.M., Vargas E., Capella D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev, 2005, vol. 20, no. 2, CD003229. doi: 10.1002/14651858.CD003229.pub2.
12.Todd M. Compression in older people. BJN, 2019, vol. 28, no. 9, pp. 566. doi: 10.12968/bjon.2019.28.9.566.
13. Nicolaides A. The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease. Adv Ther, 2020, vol. 37, suppl. 1, pp. 1-5. doi: 10.1007/s12325-019-01218-8.
14. Bogachev V.Y., Boldin B.V., Lobanov V.N. Benefits of micronized purified flavonoid fraction as adjuvant therapy on inflammatory response after sclerotherapy. Int Angiol, 2018, vol. 37, pp. 71-78. doi: 10.23736/S0392-9590.17.03868-8.
15. Mansilha A., Sousa J. Benefits of venoactive drug therapy in surgical or endovenous treatment for varicose veins: a systematic review. Int Angiol, 2019, vol. 38, no. 4, pp. 291-298. doi: 10.23736/S0392-9590.19.04216-0.
16. Jawien A., Bouskela E., Allaert F.A., Nicolaides A.N. The place of Ruscus extract, hesperidin methyl chalcone, and vitamin C in the management of chronic venous disease. Int Angiol, 2017, vol. 36, no. 1, pp. 31-41. doi: 10.23736/S0392-9590.16.03788-3.
17. Kakkos S.K., Bouskela E., Jawien A., Nicolaides A.N. New data on chronic venous disease: a new place for Cyclo 3® Fort. Int Angiol, 2018, vol. 37, no. 1, pp. 85-92. doi: 10.23736/S0392-9590.17.03935-9.
18.Kakkos S.K., Guex J.J., Lugli M., Nicolaides A.N. CEAP clinical classes C0S-C4: differences, similarities and role of Ruscus + HMC + vitamin C in patients with chronic venous disease. Int Angiol, 2020, vol. 39, no. 2, pp. 118-124. doi: 10.23736/S0392-9590.20.04341-2.
19. De Almeida Cyrino F.Z.G., Balthazar D.S., Sicuro F.L., Bouskela E. Effects of venotonic drugs on the microcirculation: Comparison between Ruscus extract and micronized diosmi ne. Clin Hemorheol Microcirc, 2018, vol. 68, no. 4, pp. 371-382. doi: 10.3233/CH-170281.
20. Nicolaides A., Kakkos S., Baekgaard N., Comerota A., de Maeseneer M., Eklof B. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Part II. Int Angiol, 2020, vol. 39, no. 3, pp. 175-240. doi: 10.23736/S0392-9590.20.04388-6.
21. Marsden G., Perry M., Kelley K., Davies A.H. Guideline Development Group. Diagnosis and management of varicose veins in the legs: summary of NICE guidance. BMJ, 2013, vol. 347, pp. 4279. doi: 10.1136/bmj. f4279.
22. Gloviczki P., Comerota A.J., Dalsing M.C. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg, 2011, vol. 53, suppl. 5, pp. 2-48. doi: 10.1016/j.jvs.2011.01.079.
23. Davies A.H. The seriousness of chronic venous disease: a review of real-world evidence. Adv Ther, 2019, vol. 36, suppl. 1, pp. 5-12. doi: 10.1007/s12325-019-0881-7.
24. Smith P. The causes of skin damage and leg ulceration in chronic venous disease. Int J Low Extrem Wounds, 2006, vol. 5, no. 3, pp. 160-168. doi: 10.1177/1534734606292429.
25.Cavezzi A., Tessari L. Foam sclerotherapy techniques: different gases and methods of preparation, catheter versus direct injection. Phlebology, 2009, vol. 24, no. 6, pp. 247-251. doi: 10.1258/phleb.2009.009061.
26.Breu F.X., Guggenbichler S. European Consensus Meeting on Foam Sclerotherapy, April, 4-6, 2003, Tegernsee, Germany. Dermatol Surg, 2004, vol. 30, pp. 709-717. doi: 10.1111/j.1524-4725.2004.30209.x.
27. Baeshko A.A. Pennaya skleroterapiya: istoriya razvitiya i sovremennye dannye [Foam sclerotherapy: history of development and current evidence.]. Novosti hirurgii, 2012, vol. 20, no 4, pp. 101-110. (in Russian).
28.Coleridge Smith P. Saphenous ablation: sclerosant or sclerofoam? Semin Vasc Surg, 2005, vol.18, no. 1, pp. 19-24. doi: 10.1053/j.semvascsurg.2004.12.007.
29. Cavezzi A., Frullini A. The role of sclerosing foam in ultrasound guided sclerotherapy of the saphenous veins of recurrent varicose veins: our personal experience. Aust N Z J Phlebol, 1999, vol. 3, pp. 49-50.
30. Tessari L., Cavezzi A., Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg, 2001, vol. 27, no. 1, pp. 58-60.
31. Jia X., Mowatt G., Burr J.M., Cassar K., Cooke J., Fraser C. Systematic review of foam sclerotherapy for varicose veins. Br J Surg, 2007, vol. 94, pp. 925-936. doi: 10.1002/bjs.5891.
32. Hamann S.A.S., Giang J., De Maeseneer M.G.R., Nijsten T.E.C., van den Bos R.R. Five year results of great saphenous vein treatment: a meta-analysis. Eur J Vasc Endovasc Surg, 2017, vol. 54, pp. 760-770. doi: 10.1016/j.ejvs.2017.08.034.
33. Rasmussen L.H., Lawaetz M., Bjoern L., Vennits B., Blemings A., Eklof B. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg, 2011, vol. 98, no 8, pp. 1079-1087. doi: 10.1002/bjs.7555.
34. Wallace T., El-Sheikha J., Nandhra S., Leung C., Mohamed A., Harwood A., Smith G., Carradice D., Chetter I. Long-term outcomes of endovenous laser ablation and conventional surgery for great saphenous varicose veins. Br J Surg, 2018, vol. 105, no. 13, pp. 1759-1767. doi: 10.1002/bjs.10961.
35. Van den Bos R.R., Neumann M., De Roos K.P. Endovenous laser ablation-induced complications: review of literature and new cases. Dermatol Surg, 2009, vol. 35, pp. 1206-1214. doi: 10.1111/j.1524-4725.2009.01215. x.
36. Sichlau M.J., Ryu R.K. Cutaneous thermal injury after endovenous laser ablation of the great saphenous vein. J Vasc Interv Radiol, 2004, vol. 15, pp. 865-867. doi: 10.1097/01.RVI.0000136968.64870.07.
37. Sun J.J., Chowdhury M.M., Sadat U., Hayes P.D., Tang T.Y. Mechanochemical ablation for treatment of truncal venous insufficiency: a review of the current literature. J Vasc Interv Radiol, 2017, vol. 28, no. 10, pp. 1422-1431. doi: 10.1016/j.jvir.2017.07.002.
38. Ciostek P., Kowalski M., Woźniak W., Miłek T., Myrcha P., Migda B. Phlebogriffe – a new device for mechanochemical ablation of incompetent saphenous veins: a pilot study. Phlebological Review, 2015, vol. 23, no. 3, pp. 72-77. doi: 10.5114/pr.2015.57466.
39. Khryshchanovich V.Y., Nebylitsin Y.S., Kosinets V.A. Efficacy of micronized purified flavonoid fraction-based venoactive therapy after endovenous mechanochemical obliteration: prospective comparative study. Drugs Real World Outcomes, 2021, vol. 8, no. 3, pp. 349-358. doi: 10.1007/s40801-021-00249-4.
40.Zubilewicz T., Terlecki P., Terlecki K., Przywara S., Rybak J., Ilzecki M. Application of endovenous mechanochemical ablation (MOCA) with Flebogrif™ to treat varicose veins of the lower extremities: a single center experience over 3 months of observation. Acta Angiologica, 2016, vol. 22, no. 4, pp. 137-142. doi: 10.5603/AA.2016.0012.
41. Johanes N., Wardhana A., Ghea C. Mechanical Occlusion Chemically Assisted Ablation (MOCA) for Saphenous Vein Insufficiency: A Meta-Analysis of a Randomized Trial. Int J Vasc Med, 2020, vol. 29. doi: 10.1155/2020/8758905.
42. Tawfik A.M., Sorour W.A., El-Laboudy M.E. Laser ablation versus mechanochemical ablation in the treatment of primary varicose veins: A randomized clinical trial. J Vasc Surg Venous and Lym Dis, 2020, vol. 8, no 2, pp. 211-215. doi: 10.1016/j.jvsv.2019.10.025.
43. Vähäaho S., Halmesmäki K., Mahmoud O., Albäck A., Noronen K., Venermo M. Three-year results of a randomized controlled trial comparing mechanochemical and thermal ablation in the treatment of insufficient great saphenous veins. J Vasc Surg Venous and Lym Dis, 2021, vol. 9, no 3, pp. 652-659. doi: 10.1016/j.jvsv.2020.08.007.
44.Mohamed A.H., Leung C., Wallace T., Smith G., Carradice D., Chetter I. A randomized controlled trial of endovenous laser ablation versus mechanochemical ablation with ClariVein in the management of superficial venous incompetence (LAMA trial). Ann Surg, 2021, vol. 273, no 6, pp. e188-e195. doi: 10.1097/SLA.0000000000003749.
45.Smith S.R., Goldman M.P. Tumescent anesthesia in ambulatory phlebectomy. Dermatol Surg, 1998, vol. 24, pp. 453. doi: 10.1111/j.1524-4725.1998.tb04187.x.
46.Mansilha A., Sousa J. Benefits of venoactive drug therapy in surgical or endovenous treatment for varicose veins: a systematic review. Int Angiol, 2019, vol. 38, no. 4, pp. 291-298. doi: 10.23736/S0392-9590.19.04216-0.
47. Hartmann K., Stenger D., Hartmann M., Rafi-Stenger L. Endochirurgie versus offene Chirugie der Varikose. Versuch einer Wertung. Hautarzt, 2017, vol. 68, no. 8, pp. 603-613. doi: 10.1007/s00105-017-3996-2.
48. O’Donnell T.F., Passman M.A., Marston W.A., Ennis W.J., Dalsing M., Kistner R.L. Management of venous leg ulcers: Clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum. J Vasc Surg, 2014, vol. 60, pp. 3S-59S. doi: 10.1016/j.jvs.2014.04.049.
49. Mahenthiran A.K., Natarajan J.P., Bertges D.J., Huffman K.M., Eldrup-Jorgensen J., Lemmon G.W. Impact of COVID-19 on the Society for Vascular Surgery Vascular Quality Initiative Venous Procedure Registries (varicose vein and inferior vena cava filter). J Vasc Surg Venous Lymphat Disord, 2021, vol. 9, no. 5, pp. 1093-1098. doi: 10.1016/j.jvsv.2021.01.002.

Полнотекстовая статья

Скачать статью

Формат файла: pdf (1.11 Мб)

→ Главная → 2022 том 6, №2